ImageneBio, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
ImageneBio, Inc. (IMA) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of -$12.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-12.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2024-03-12
- ImageneBio, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-12-31 was $0.00.
- ImageneBio, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$12.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$12.00K 10-K · filed 2024-03-12 | |
| 2022-09-30 | -$12.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |